Kyowa Kirin Co., Ltd

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, sells, and import/export of pharmaceuticals products worldwide. It's pipeline consist of OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4083/AMG 45, which is in Phase III and II clinical trial for the treatment of atopic dermatitis and prurigo nodularis, and asthma; OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A; ziftomenib, which is in Phase II and I clinical trial for the treatment of acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123, which is in Phase I clinical trial for the treatment of x-linked hypophosphatemia; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK4277, which is in Phase I clinical trial for the treatment of systemic and cutaneous lupus erythematosus; and KK2260 and KK2269 that are in Phase I clinical trial for the treatment of solid tumors. It also develops POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein that produces platelet; Crysvita, a recombinant human monoclonal IgG1 antibody; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and LUMICEF, a biological treatment for moderate to severe plaque psoriasis. In addition, it offers G-Lasta; Duvroq; PHOZEVEL; KK8398; KHK4827; and OTL-200. It has an agreement with Amgen Inc. and Kura Oncology. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.